Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K. Fan F, et al. Among authors: vallet s. Cancer Lett. 2014 Feb 28;343(2):286-94. doi: 10.1016/j.canlet.2013.09.042. Epub 2013 Oct 8. Cancer Lett. 2014. PMID: 24120758
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. Fan F, et al. Among authors: vallet s. Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18. Leukemia. 2021. PMID: 34007044 Free PMC article.
The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.
Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, Tassone P, Jaeger D, Podar K. Fan F, et al. Among authors: vallet s. Leukemia. 2017 Jul;31(7):1570-1581. doi: 10.1038/leu.2016.358. Epub 2016 Nov 28. Leukemia. 2017. PMID: 27890927
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jäger D, Olson DL, Sattler M, Chauhan D, Anderson KC. Podar K, et al. Among authors: vallet s. Br J Haematol. 2011 Nov;155(4):438-48. doi: 10.1111/j.1365-2141.2011.08864.x. Epub 2011 Sep 19. Br J Haematol. 2011. PMID: 21923653 Free article.
Adoptive cell therapy in multiple Myeloma.
Vallet S, Pecherstorfer M, Podar K. Vallet S, et al. Expert Opin Biol Ther. 2017 Dec;17(12):1511-1522. doi: 10.1080/14712598.2017.1375095. Epub 2017 Sep 6. Expert Opin Biol Ther. 2017. PMID: 28857616 Review.
175 results